Article info

Protocol
Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial

Authors

  1. Correspondence to Professor Christian Morath; christian.morath{at}med.uni-heidelberg.de
View Full Text

Citation

Morath C, Schmitt A, Schmitt M, et al
Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial

Publication history

  • Received July 7, 2022
  • Accepted October 17, 2022
  • First published November 11, 2022.
Online issue publication 
December 29, 2023
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.